EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effectiveness and Safety of Stapokibart in Chinese Patients With Allergic Rhinitis: A Single‐Center Retrospective Study

Dan Liang, Li‐Hong Yang, Xian He

Clinical and Translational Allergy · 2026-11 · 16 (11)

DOI: 10.1002/clt2.70231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 20.11.2026. Verfasst von Dan Liang und 2 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Stapokibart is an anti‐interleukin‐4 receptor alpha subunit (IL‐4Rα) monoclonal antibody, which has been approved in China for seasonal allergic rhinitis. We evaluated its effectiveness and safety in patients with allergic rhinitis in a real‐world clinical setting.

Methods

We conducted a single‐center retrospective cohort study of adults with allergic rhinitis. Patients received subcutaneous stapokibart 300 mg (loading dose 600 mg) every 2 weeks for ≥ 4 weeks. Efficacy assessments included reflective total nasal symptom score (rTNSS), reflective total ocular symptom score (rTOSS), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), and visual analogue scale scores for symptoms of comorbidities at week 2. The incidence of treatment‐emergent adverse events (TEAEs) was also assessed.

Results

Between February 11 and May 1, 2025, 114 patients were included (median age 36 years [range 18–70]; 50.9% female), of whom 87.7% experienced type 2 inflammation‐related comorbidities. At week 2, significant reductions from baseline were observed in the rTNSS (−7.0 [95% CI ‒7.4, −6.6]), rTOSS (−1.9 [95% CI ‒2.3, −1.6]), and RQLQ score (−2.3 [95% CI ‒2.5, −2.2]) (all p < 0.0001). Symptoms of type 2 inflammation‐related comorbidities also improved. During stapokibart treatment, the number of concomitant medications decreased ( p < 0.0001). After treatment discontinuation, 56 patients (55.4%) required no additional medication. TEAEs were reported in 8 patients (7.0%), all were mild‐to‐moderate. The incidence of drug‐related TEAEs was 1.6%. The common TEAEs were conjunctivitis and injection site reaction.

Conclusion

Stapokibart may be a potential treatment option for Chinese patients with improved allergic rhinitis symptoms, reduced medication use, and a favorable safety profile.

Zitieren

APA

Liang, D., Yang, L., & He, X. (2026). Effectiveness and Safety of Stapokibart in Chinese Patients With Allergic Rhinitis: A Single‐Center Retrospective Study. Clinical and Translational Allergy, 16(11). https://doi.org/10.1002/clt2.70231

Vancouver

Liang D, Yang L, He X. Effectiveness and Safety of Stapokibart in Chinese Patients With Allergic Rhinitis: A Single‐Center Retrospective Study. Clinical and Translational Allergy. 2026;16(11). doi:10.1002/clt2.70231

BibTeX
@article{Liang2026,
  author = {Liang, Dan and Yang, Li‐Hong and He, Xian},
  title = {Effectiveness and Safety of Stapokibart in Chinese Patients With Allergic Rhinitis: A Single‐Center Retrospective Study},
  journal = {Clinical and Translational Allergy},
  year = {2026},
  volume = {16},
  number = {11},
  doi = {10.1002/clt2.70231}
}
Kostenlos starten →